Snowden Capital Advisors’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $24.9M | Sell |
27,038
-3,412
| -11% | -$3.46M | 0.66% | 25 |
|
|
2025
Q4 | $32.7M | Buy |
30,450
+1,946
| +7% | +$1.86M | 0.85% | 18 |
|
|
2025
Q3 | $21.7M | Sell |
28,504
-195
| -0.7% | -$145K | 0.59% | 26 |
|
|
2025
Q2 | $22.4M | Sell |
28,699
-304
| -1% | -$236K | 0.66% | 21 |
|
|
2025
Q1 | $24M | Buy |
29,003
+953
| +3% | +$793K | 0.77% | 19 |
|
|
2024
Q4 | $21.7M | Sell |
28,050
-4,622
| -14% | -$3.83M | 0.67% | 22 |
|
|
2024
Q3 | $28.9M | Buy |
32,672
+2,053
| +7% | +$1.85M | 0.86% | 14 |
|
|
2024
Q2 | $27.7M | Sell |
30,619
-392
| -1% | -$314K | 0.82% | 13 |
|
|
2024
Q1 | $24.1M | Buy |
31,011
+7,658
| +33% | +$5.45M | 0.75% | 13 |
|
|
2023
Q4 | $13.6M | Buy |
23,353
+4,792
| +26% | +$2.8M | 0.52% | 24 |
|
|
2023
Q3 | $9.97M | Sell |
18,561
-15,237
| -45% | -$7.85M | 0.42% | 36 |
|
|
2023
Q2 | $15.9M | Buy |
33,798
+7,139
| +27% | +$2.99M | 0.57% | 29 |
|
|
2023
Q1 | $9.16M | Buy |
26,659
+398
| +2% | +$134K | 0.36% | 47 |
|
|
2022
Q4 | $9.61M | Buy |
26,261
+564
| +2% | +$200K | 0.4% | 40 |
|
|
2022
Q3 | $8.31M | Buy |
25,697
+2,347
| +10% | +$744K | 0.38% | 45 |
|
|
2022
Q2 | $7.57M | Buy |
23,350
+4,938
| +27% | +$1.48M | 0.34% | 57 |
|
|
2022
Q1 | $5.27M | Buy |
18,412
+15,404
| +512% | +$3.96M | 0.21% | 125 |
|
|
2021
Q4 | $831K | Sell |
3,008
-5,800
| -66% | -$1.47M | 0.04% | 362 |
|
|
2021
Q3 | $2.04M | Buy |
8,808
+964
| +12% | +$238K | 0.1% | 251 |
|
|
2021
Q2 | $1.8M | Buy |
7,844
+231
| +3% | +$46.4K | 0.09% | 280 |
|
|
2021
Q1 | $1.42M | Buy |
7,613
+1,403
| +23% | +$274K | 0.08% | 285 |
|
|
2020
Q4 | $1.05M | Buy |
6,210
+1,149
| +23% | +$172K | 0.07% | 299 |
|
|
2020
Q3 | $749K | Sell |
5,061
-49
| -1% | -$7.58K | 0.06% | 308 |
|
|
2020
Q2 | $839K | Buy |
5,110
+744
| +17% | +$114K | 0.07% | 287 |
|
|
2020
Q1 | $606K | Buy |
4,366
+2,462
| +129% | +$338K | 0.07% | 310 |
|
|
2019
Q4 | $250K | Buy |
1,904
+66
| +4% | +$7.65K | 0.02% | 522 |
|
|
2019
Q3 | $206K | Sell |
1,838
-125
| -6% | -$13.9K | 0.02% | 497 |
|
|
2019
Q2 | $217K | Buy |
1,963
+243
| +14% | +$28.6K | 0.02% | 478 |
|
|
2019
Q1 | $223K | Buy |
+1,720
| New | +$209K | 0.02% | 467 |
|
|
2016
Q4 | – | Sell |
-3,753
| Closed | -$301K | – | 308 |
|
|
2016
Q3 | $301K | Sell |
3,753
-218
| -5% | -$17.4K | 0.08% | 245 |
|
|
2016
Q2 | $313K | Sell |
3,971
-5
| -0.1% | -$376 | 0.09% | 221 |
|
|
2016
Q1 | $286K | Buy |
+3,976
| New | +$301K | 0.1% | 228 |
|
Other funds holding LLY
VCM
VPM
Snowden Capital Advisors's LLY Position: Q1 2026 in Review
Snowden Capital Advisors reduced its Eli Lilly (LLY) stake by 11% in Q1 2026, selling an estimated $3.46M and leaving 27,038 shares worth $24.9M. The position accounts for 0.66% of the portfolio, ranked #25.
Snowden Capital Advisors first reported a position in LLY in Q1 2016 and has held it in 32 quarters since. The position peaked at $32.7M in Q4 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.
- Snowden Capital Advisors held 27,038 shares of Eli Lilly worth $24.9M as of Q1 2026.
- Snowden Capital Advisors sold 3,412 Eli Lilly shares in Q1 2026, an estimated $3.46M.
- Eli Lilly made up 0.66% of Snowden Capital Advisors's portfolio in Q1 2026, its #25 holding.
- Snowden Capital Advisors first reported a position in Eli Lilly in Q1 2016 and has held it in 32 quarters since.
- Snowden Capital Advisors's Eli Lilly position peaked at $32.7M in Q4 2025.
- 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.
Based on Snowden Capital Advisors's 13F filing for Q1 2026, filed 15 May 2026.